Leading HIV Researchers and Argos Therapeutics, Inc. Highlight Importance of Immunotherapy in HIV Eradication Efforts
6/13/2013 8:38:40 AM
More...
|
Argos Therapeutics, Inc. Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy
6/11/2013 9:38:41 AM
More...
|
Argos Therapeutics, Inc. Announces U.S. and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy
6/10/2013 1:50:17 PM
More...
|
Argos Therapeutics, Inc. to Present at the Sachs Cancer Bio Partnering Forum
5/20/2013 9:43:33 AM
More...
|
Argos Therapeutics, Inc. Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
5/8/2013 1:53:19 PM
More...
|
Argos Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare Conference
4/30/2013 2:27:21 PM
More...
|
Argos Therapeutics, Inc. Welcomes Jean Lamarre to Board of Directors
3/13/2013 12:27:23 PM
More...
|
Argos Therapeutics, Inc. Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
3/4/2013 11:28:51 AM
More...
|
Argos Therapeutics, Inc. Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma
2/15/2013 9:42:11 AM
More...
|
Argos Therapeutics, Inc. to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum
1/28/2013 9:04:29 AM
More...
|
|